JP2013542223A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542223A5 JP2013542223A5 JP2013536669A JP2013536669A JP2013542223A5 JP 2013542223 A5 JP2013542223 A5 JP 2013542223A5 JP 2013536669 A JP2013536669 A JP 2013536669A JP 2013536669 A JP2013536669 A JP 2013536669A JP 2013542223 A5 JP2013542223 A5 JP 2013542223A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- aryl
- alkyl
- group
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 146
- 125000002947 alkylene group Chemical group 0.000 claims description 124
- 125000003118 aryl group Chemical group 0.000 claims description 120
- 150000001875 compounds Chemical class 0.000 claims description 54
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 52
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 47
- 125000001072 heteroaryl group Chemical group 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 28
- 150000002431 hydrogen Chemical class 0.000 claims description 27
- 229920006395 saturated elastomer Polymers 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000000651 prodrug Substances 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 102000004452 Arginase Human genes 0.000 claims description 16
- 108700024123 Arginases Proteins 0.000 claims description 16
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 claims description 14
- 101710186578 Arginase-2, mitochondrial Proteins 0.000 claims description 14
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 13
- 125000004450 alkenylene group Chemical group 0.000 claims description 13
- 125000004419 alkynylene group Chemical group 0.000 claims description 13
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 13
- 125000000732 arylene group Chemical group 0.000 claims description 13
- 125000004104 aryloxy group Chemical group 0.000 claims description 13
- 229910052796 boron Inorganic materials 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 125000004043 oxo group Chemical group O=* 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 6
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
- 201000001881 impotence Diseases 0.000 claims description 5
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- BXGZDYTYKYZJJN-UHFFFAOYSA-N 1-amino-2-(3-boronopropyl)cyclohexane-1-carboxylic acid Chemical compound OC(=O)C1(N)CCCCC1CCCB(O)O BXGZDYTYKYZJJN-UHFFFAOYSA-N 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 3
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40676010P | 2010-10-26 | 2010-10-26 | |
| US61/406,760 | 2010-10-26 | ||
| PCT/US2011/056844 WO2012058065A1 (en) | 2010-10-26 | 2011-10-19 | Boronates as arginase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542223A JP2013542223A (ja) | 2013-11-21 |
| JP2013542223A5 true JP2013542223A5 (enExample) | 2014-12-04 |
| JP5909239B2 JP5909239B2 (ja) | 2016-04-26 |
Family
ID=44913403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013536669A Active JP5909239B2 (ja) | 2010-10-26 | 2011-10-19 | アルギナーゼ阻害剤としてのボロネート |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9233985B2 (enExample) |
| EP (3) | EP3034509B1 (enExample) |
| JP (1) | JP5909239B2 (enExample) |
| CN (2) | CN106008569B9 (enExample) |
| AU (1) | AU2011320732B2 (enExample) |
| BR (1) | BR112013010099B1 (enExample) |
| CA (1) | CA2815536C (enExample) |
| DK (1) | DK2632927T3 (enExample) |
| ES (2) | ES2568680T3 (enExample) |
| HK (1) | HK1223104A1 (enExample) |
| HR (1) | HRP20160305T1 (enExample) |
| HU (1) | HUE027317T2 (enExample) |
| IL (1) | IL225926A (enExample) |
| MX (1) | MX336381B (enExample) |
| PL (1) | PL2632927T3 (enExample) |
| RS (1) | RS54750B1 (enExample) |
| SI (1) | SI2632927T1 (enExample) |
| SM (1) | SMT201600141B (enExample) |
| WO (1) | WO2012058065A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| RU2599791C2 (ru) | 2010-08-10 | 2016-10-20 | Ремпекс Фармасьютикэлз, Инч. | Циклические бороновые кислотно-эфирные производные и их использование в терапии |
| EP3034509B1 (en) * | 2010-10-26 | 2020-04-22 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| CN104540836B (zh) * | 2012-04-18 | 2016-11-09 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
| AU2014204045B2 (en) | 2013-01-04 | 2018-10-18 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3134546A4 (en) * | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| US10385074B2 (en) | 2014-05-05 | 2019-08-20 | Rempex Pharmaceuticals, Inc. | Synthesis of boronate salts and uses thereof |
| WO2015171398A1 (en) | 2014-05-05 | 2015-11-12 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| AU2015284307A1 (en) | 2014-07-01 | 2017-02-02 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2016149393A1 (en) * | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| AU2016281620B2 (en) * | 2015-06-23 | 2021-07-22 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PT3356413T (pt) | 2015-10-01 | 2022-04-04 | Potenza Therapeutics Inc | Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas |
| DK3368541T3 (da) * | 2015-10-30 | 2020-06-29 | Calithera Biosciences Inc | Sammensætninger og metoder til inhibiering af arginaseaktivitet |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| US11291674B2 (en) | 2016-11-08 | 2022-04-05 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| WO2018119440A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| JOP20190203A1 (ar) | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
| KR20200008578A (ko) | 2017-05-12 | 2020-01-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법 |
| BR112020007138B1 (pt) | 2017-10-11 | 2023-03-21 | Qpex Biopharma, Inc | Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos |
| CN111491937A (zh) * | 2017-12-22 | 2020-08-04 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的杂环化合物 |
| SG11202007739XA (en) | 2018-02-17 | 2020-09-29 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| WO2019173188A1 (en) * | 2018-03-05 | 2019-09-12 | Arcus Biosciences, Inc. | Arginase inhibitors |
| US12215116B2 (en) * | 2018-03-13 | 2025-02-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| AU2019246728A1 (en) | 2018-03-29 | 2020-08-27 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| WO2019205979A1 (zh) * | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
| WO2019218904A1 (zh) * | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
| EP3810615B1 (en) | 2018-06-20 | 2026-01-28 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| EP3880685B1 (en) * | 2018-11-16 | 2025-06-18 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP3897622B1 (en) * | 2018-12-18 | 2026-01-14 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| CN113614095B (zh) * | 2019-02-06 | 2024-08-23 | 广东新契生物医药科技有限公司 | 作为精氨酸酶抑制剂的烷基硼酸类化合物 |
| MY206577A (en) | 2019-02-08 | 2024-12-24 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP4004004A1 (en) * | 2019-07-23 | 2022-06-01 | AstraZeneca AB | Arginase inhibitors and methods of use thereof |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| US20230140132A1 (en) * | 2020-01-07 | 2023-05-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| IL299612A (en) | 2020-07-02 | 2023-03-01 | Incyte Corp | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| WO2023283332A1 (en) * | 2021-07-07 | 2023-01-12 | Emory University | Uses of arginase inhibitors for managing kidney disease and cardiovascular conditions |
| WO2023191116A2 (en) | 2022-01-21 | 2023-10-05 | Opiyo Sammy Oyoo | Improved suramin methods and compositions |
| IL315647A (en) | 2022-03-17 | 2024-11-01 | Incyte Corp | Tricyclic urea compounds as Jak2 and 617f inhibitors |
| WO2024086273A1 (en) | 2022-10-21 | 2024-04-25 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| WO2024191996A1 (en) | 2023-03-13 | 2024-09-19 | Incyte Corporation | Bicyclic ureas as kinase inhibitors |
| WO2026076207A1 (en) | 2024-10-04 | 2026-04-09 | Incyte Corporation | Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1009890A (en) | 1911-02-09 | 1911-11-28 | Michael F Brauer | Dumping attachment for headers. |
| US1006597A (en) | 1911-05-26 | 1911-10-24 | Rail Joint Co | Insulated rail-joint. |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| DE69818675T2 (de) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| AU9797998A (en) | 1997-10-10 | 1999-05-03 | Trustees Of The University Of Pennsylvania, The | Compositions and methods for inhibiting arginase activity |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| WO2002004465A1 (en) | 2000-07-06 | 2002-01-17 | Fal Diagnostics | Methods and kits for the detection of arginine compounds |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1915143A4 (en) | 2005-07-01 | 2009-11-11 | Univ Johns Hopkins | ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE |
| MX2009005370A (es) | 2006-11-21 | 2009-10-16 | Univ Groningen | Uso de inhibidores de arginasa en el tratamiento de asma y rinitis alergica. |
| CN101755130B (zh) | 2007-07-12 | 2012-10-17 | 山洋电气株式会社 | 双重反转式轴流鼓风机 |
| CN103191129A (zh) | 2007-10-12 | 2013-07-10 | C.T.辨析有限公司 | 治疗眼睛病症的脂氧化物类化合物 |
| US20110129456A1 (en) | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
| WO2010085797A2 (en) | 2009-01-26 | 2010-07-29 | The Trustees Of University Of Pennsylvania | Arginase inhibitors and methods of use |
| EP2560978B1 (en) | 2010-04-22 | 2019-01-30 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| EP3034509B1 (en) | 2010-10-26 | 2020-04-22 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| RU2019121905A (ru) | 2010-12-31 | 2019-09-03 | Астразенека Юкей Лимитед | Ингибиторы аргиназы и способы их применения |
| CA2852685C (en) | 2011-10-19 | 2019-02-26 | Mars, Incorporated | Inhibitors of arginase and their therapeutic application |
| KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| CN104540836B (zh) | 2012-04-18 | 2016-11-09 | 马尔斯公司 | 作为精氨酸酶抑制剂的环约束类似物 |
| SG11201503459SA (en) | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| CN105473550B (zh) | 2013-07-01 | 2019-02-15 | 百时美施贵宝公司 | Ido抑制剂 |
| WO2015061752A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| KR20170129896A (ko) | 2015-03-20 | 2017-11-27 | 새미 오유 오피요 | 악성 신생물에 대한 수라민 및 아르기나아제 억제제의 용도 |
| AU2016281620B2 (en) | 2015-06-23 | 2021-07-22 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| DK3368541T3 (da) | 2015-10-30 | 2020-06-29 | Calithera Biosciences Inc | Sammensætninger og metoder til inhibiering af arginaseaktivitet |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2018119440A1 (en) | 2016-12-22 | 2018-06-28 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| KR20200008578A (ko) | 2017-05-12 | 2020-01-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | (3R,4S)-3-아세트아미도-4-알릴-N-(tert-부틸)피롤리딘-3-카복스아미드의 제조방법 |
-
2011
- 2011-10-19 EP EP16150285.1A patent/EP3034509B1/en active Active
- 2011-10-19 RS RS20160243A patent/RS54750B1/sr unknown
- 2011-10-19 CN CN201610322649.4A patent/CN106008569B9/zh not_active Expired - Fee Related
- 2011-10-19 EP EP11779904.9A patent/EP2632927B1/en active Active
- 2011-10-19 CN CN201180057717.4A patent/CN103249737B/zh not_active Expired - Fee Related
- 2011-10-19 ES ES11779904.9T patent/ES2568680T3/es active Active
- 2011-10-19 ES ES16150285T patent/ES2794006T3/es active Active
- 2011-10-19 HU HUE11779904A patent/HUE027317T2/en unknown
- 2011-10-19 AU AU2011320732A patent/AU2011320732B2/en not_active Ceased
- 2011-10-19 PL PL11779904.9T patent/PL2632927T3/pl unknown
- 2011-10-19 MX MX2013004491A patent/MX336381B/es unknown
- 2011-10-19 JP JP2013536669A patent/JP5909239B2/ja active Active
- 2011-10-19 US US13/276,806 patent/US9233985B2/en active Active
- 2011-10-19 EP EP20162218.0A patent/EP3719024A1/en active Pending
- 2011-10-19 CA CA2815536A patent/CA2815536C/en active Active
- 2011-10-19 SI SI201130766A patent/SI2632927T1/sl unknown
- 2011-10-19 BR BR112013010099-0A patent/BR112013010099B1/pt not_active IP Right Cessation
- 2011-10-19 WO PCT/US2011/056844 patent/WO2012058065A1/en not_active Ceased
- 2011-10-19 HR HRP20160305TT patent/HRP20160305T1/hr unknown
- 2011-10-19 DK DK11779904.9T patent/DK2632927T3/en active
-
2013
- 2013-04-24 IL IL225926A patent/IL225926A/en active IP Right Grant
-
2015
- 2015-02-04 US US14/614,115 patent/US9440995B2/en active Active
-
2016
- 2016-05-19 SM SM201600141T patent/SMT201600141B/it unknown
- 2016-07-12 US US15/207,902 patent/US10098902B2/en active Active
- 2016-09-23 HK HK16111212.1A patent/HK1223104A1/en unknown
-
2018
- 2018-08-21 US US16/107,087 patent/US10603330B2/en not_active Expired - Fee Related
-
2020
- 2020-02-19 US US16/794,905 patent/US11389464B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022551185A5 (enExample) | ||
| JP2013502430A5 (enExample) | ||
| SI2498610T1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| RU2012146819A (ru) | Ингибиторы аргиназы и их терапевтические применения | |
| WO2012107706A8 (en) | Phenothiazine diaminium salts and their use | |
| JP2020520893A5 (enExample) | ||
| JP2015511638A5 (enExample) | ||
| JP2010501584A5 (enExample) | ||
| JP2014528467A5 (enExample) | ||
| JP2016520618A5 (enExample) | ||
| JP2018519343A5 (enExample) | ||
| CA2637765A1 (en) | Benzamide and heteroarene derivatives | |
| JP2013502431A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| JP2018518537A5 (enExample) | ||
| JP2014508781A5 (enExample) | ||
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| JP2014527974A5 (enExample) | ||
| JP2010031025A5 (enExample) | ||
| JP2012505871A5 (enExample) | ||
| WO2012018534A3 (en) | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases | |
| RU2016125705A (ru) | Замещенные бензоазепины в качестве модуляторов тoll-подобных рецепторов | |
| BR112013025634A2 (pt) | inibidores de hsp90 | |
| RU2011127079A (ru) | Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с | |
| JP2019500387A5 (enExample) |